CEO SUMMARY: Proteomics-based technology is developing rapidly. The strategic collaboration announced last month between Ciphergen Biosystems and Quest Diagnostics Incorporated is potentially worth $25 million. It is an expensive bet that next-generation proteomics tests soon to enter the clinical marketplace will provide high clinical utility and give physicians new diagnostic tools. NEW PROTEOMIC-BASED TECHNOLOGIES ARE …
Proteomic Tests Poised For Clinical Market Read More »
